Recent Updates
Recently added Catalysts
CLYM Positive Sentiment Score: 75/100

Climb Bio to Present at William Blair’s Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19

Friday, October 4, 2024 1 min read
Key Takeaway: Climb Bio, Inc. (Nasdaq: CLYM) will present and host investor meetings at the upcoming William Blair event focused on transforming autoimmune diseases through CD19 targeting. This event is scheduled for October 16, 2024, in New York, NY. Climb Bio is a clinical-stage biotechnology company known for its development of therapeutics for immune-mediated diseases, with its lead candidate, budoprutug, being an anti-CD19 monoclonal antibody.

Market Sentiment Analysis

POSITIVE FACTORS

  • Climb Bio is engaged in promising research targeting autoimmune diseases.
  • The upcoming presentation at a notable conference indicates strong investor interest.
  • The lead product, budoprutug, shows potential in treating various immune-mediated diseases.

Full Press Release Details

WELLESLEY, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will present and host investor meetings at William Blair’s Transforming Autoimmune Diseases by Targeting CD19 event being held in New York, NY on Wednesday, October 16, 2024.
About Climb Bio, Inc.
Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For more information, please visit climbbio.com.
chris.brinzey@westwicke.com
jon.yu@westwicke.com

Frequently Asked Questions

What event will Climb Bio attend in October 2024?

Climb Bio will participate in William Blair’s event on autoimmune diseases.

What is Climb Bio's lead product candidate?

Climb Bio's lead candidate is budoprutug, an anti-CD19 monoclonal antibody.

What diseases does budoprutug target?

Budoprutug aims to treat various B-cell mediated diseases.

Where is Climb Bio located?

Climb Bio, Inc. is based in Wellesley, Massachusetts.

When is the investor meeting scheduled?

The investor meeting is scheduled for October 16, 2024.

Tags: CLYM Viatris Investor Conferences Healthcare autoimmune diseases budoprutug CD19 biotechnology
Last updated: Oct 4, 2024